Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it ...

A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...

Exciting news in the biotech industry as positive phase 2 results for sevasemten in BMD drive long-term investment potential ...

UC Davis Health has premiered a new documentary on a family’s urgent journey across the globe to get their toddler in a clinical trial for patients with Duchenne Muscular Dystrophy, or DMD.

Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy.

Dalton “D” Harvey has dreamed of being a firefighter his entire life. Escambia County firefighters helped make that dream ...

New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective ...

Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...

Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...

UHealth and Holtz Children’s Hospital physicians are exploring a new gene therapy called ELEVIDYS to treat older Duchenne muscular dystrophy (DMD) patients. The therapy delivers a functional ...